FDA supplemental approval: Methadone Hydrochloride (REMS)

AI Summary

This is an FDA supplemental approval (REMS) for methadone hydrochloride tablets (5 mg and 10 mg formulations) submitted by Aurolife Pharma LLC, approved on 18 June 2026. The record documents a regulatory action establishing risk evaluation and mitigation strategy (REMS) requirements but contains no clinical trial results, efficacy data, or safety findings.

Plain-language summary

FDA supplemental approval for methadone hydrochloride REMS; establishes regulatory requirements but does not report clinical trial outcomes or efficacy evidence.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory action establishes REMS requirements for methadone hydrochloride but does not provide clinical evidence of efficacy, safety comparisons, or outcome data. Clinicians should refer to the approved labeling and REMS documentation for prescribing requirements and risk mitigation expectations.

Caveats

• Record does not contain clinical trial results or efficacy data
• No safety or adverse event outcomes reported
• No comparative clinical evidence or study population data
• REMS requirements and implementation details not specified in this regulatory record

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.